Clinical trials: Precancerous/Nonmalignant Condition
Extensive Photodamage, Actinic Keratosis
Treatment of Field Cancerization for Reduction in Tumor Burden - A Prospective Study
This project aims to treat field cancerization ( pre-skin cancers) in a manner that will reduce the future pre-skin cancers and non-melanoma skin cancers in patients with significant photodamage.
- Conditions
- Extensive Photodamage, Actinic Keratosis, History of Numerous Skin Cancers
- Trial name
- NCT02150863
- Testing
- Ultrapulse Carbon Dioxide Laser, Cellutome epidermal harvesting system
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Massachusetts General Hospital
Keratosis
Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis
Actinic keratosis (AK) is a skin condition that shows up on skin routinely exposed to the sun, such as the face, scalp, shoulders, chest, back, arms, and hands.
- Trial name
- NCT00116649
- Testing
- imiquimod cream
- Where
- 32 sites in United States
- Volunteers
- 551 people
- Sponsor
- Graceway Pharmaceuticals, LLC
Actinic Keratoses
Follow-up Study to Evaluate Sustained Clearance Rates of Actinic Keratoses up to One Year
The objective of this study was to obtain long-term sustained clearance rates for subjects previously treated with imiquimod creams in studies GW01-0702, GW01-0703, GW01-0704 and GW01-0705.
- Trial name
- NCT00668733
- Volunteers
- 179 people
- Sponsor
- Graceway Pharmaceuticals, LLC
Erythroplakia, Oral Leukoplakia
Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia
This phase IIb trial tests whether metformin works in preventing oral cancer in patients with oral leukoplakia (white patches) or erythroplakia (red patches). Metformin is in a class of drugs called biguanides.
- Trial name
- NCT05237960
- Testing
- Biopsy, Biospecimen Collection, Extended Release Metformin Hydrochloride
- Where
- 10 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- University of Arizona
Cervical Intraepithelial Neoplasia, Uterine Cervical Dysplasia
Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix
A-007 is an investigational therapy which may be effective in the treatment of pre-cancerous cervical dysplasia (abnormal cell growth).
- Trial name
- NCT00285207
- Testing
- A007
- Where
- 29 sites in United States
- Volunteers
- 147 people
- Sponsor
- Tigris Pharmaceuticals
Barrett's Esophagus
Polar Wand Carbon Dioxide Cryotherapy for Barrett's Esophagus
The purpose of this pilot study is to provide an initial assessment of the feasibility, safety and efficacy of Polar Wand carbon dioxide cryotherapy for treatment of Barrett's low grade and high grade dysplasia by use in a small…
- Trial name
- NCT01477177
- Testing
- Polar Wand carbon dioxide cryotherapy
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Mayo Clinic
Barrett's Esophagus
YF476 in Barrett's Esophagus
A phase 2, randomised, double-blind, out-patient trial to determine if YF476 is a safe and effective treatment in patients with Barrett's esophagus.
- Trial name
- NCT02597712
- Testing
- YF476
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 27 people
- Sponsor
- Trio Medicines Ltd.
Actinic Keratosis
A Study of Tirbanibulin on the Wellbeing of Participants With Actinic Keratoses
The purpose of the study is to assess treatment satisfaction on Day 57 in participants with Actinic Keratoses (AK) of the face or scalp following treatment with tirbanibulin ointment 1 percent (%) administered once daily for 5…
- Trial name
- NCT05741294
- Testing
- Tirbanibulin 2.5 mg ointment
- Where
- 37 sites in Italy, Spain
- Volunteers
- 334 people
- Sponsor
- Almirall, S.A.
Actinic Keratosis, Warts
Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer
Participants on immunosuppressive therapy, e.g., organ recipients, had higher occurrence of AK (Actinic Keratosis) than the untreated population.
- Conditions
- Actinic Keratosis, Warts, Basal Cell Carcinoma, Bowens Disease
- Trial name
- NCT00472459
- Testing
- Photodynamic therapy with Metvix 160 mg/g cream
- Where
- 11 sites in Denmark, Germany and 3 more
- Volunteers
- 82 people
- Sponsor
- Galderma R&D
Actinic Keratosis
Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively
The objective of the trial is to investigate the Safety of LEO 43204 0.018%, 0.037% and 0.1% for actinic keratosis applied once daily for three consecutive days on face/chest, scalp and trunk/extremities, respectively.
- Trial name
- NCT02305888
- Testing
- LEO 43204
- Where
- United States
- Volunteers
- 189 people
- Sponsor
- LEO Pharma
Precancerous Condition
Activating Collaborative CIS Support Via Targeted Provider Mailing
RATIONALE: Receiving a reminder letter from their doctor with questions to ask the Cancer Information Service may be more effective than a standard reminder letter in helping patients who have had an abnormal Pap test keep their…
- Trial name
- NCT00873288
- Testing
- Usual care mailing intervention, CIS support mailing intervention
- Where
- 2 sites in United States
- Volunteers
- 254 people
- Sponsor
- Northwestern University
Actinic Keratosis
Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up
The objective of the trial is to compare the short term efficacy of LEO 43204 gel with vehicle gel in AK on face or chest when applied topically once daily for 3 consecutive days as field treatment
- Trial name
- NCT02549339
- Testing
- LEO 43204 gel, Vehicle gel
- Where
- United States
- Volunteers
- 383 people
- Sponsor
- LEO Pharma
Human Papillomavirus Infection
Clinical Evaluation of the APTIMA® HPV Assay Using the TIGRIS® System
The purpose of this study is to provide data on the performance of the APTIMA HPV Assay using the TIGRIS System in detecting HPV types that may cause cervical cancer.
- Trial name
- NCT00973362
- Testing
- APTIMA HPV Assay, FDA-Approved HPV DNA Test
- Where
- 17 sites in United States
- Volunteers
- 12,896 people, healthy volunteers welcome
- Sponsor
- Gen-Probe, Incorporated
Cervical Intraepithelial Neoplasia
A Follow-up Extension Study to Evaluate the Persistence of Immune Response to GSK Biologicals' HPV Vaccine in Healthy Chinese Female Subjects Who Received Three Doses of the Vaccine in the HPV-058 Study
The purpose of this study is to evaluate the persistence of immune response in subjects who received the HPV-16/18 vaccine, seven to eight years after the last dose of primary vaccination in the HPV-058 study.
- Trial name
- NCT03355820
- Testing
- Blood sampling for antibody determination
- Where
- China
- Volunteers
- 228 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Barrett Esophagus
Cap Assisted Upper Endoscopy Versus High Definition White Light Endoscopy and Narrow Band Imaging Alone In The Detection Of Visible Lesions Barrett's Esophagus: A Randomized Tandem Study
The hypothesis is that the addition of a transparent cap to the end of the endoscope will increase the detection and diagnostic yield of visible lesions in Barrett's esophagus.
- Trial name
- NCT03417570
- Testing
- Esophagogastroduodenoscopy with high definition-white light end endoscopy (HD-WLE) and narrow band imaging (NBI), Olympus Disposable Distal Attachment Cap
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Washington University School of Medicine
Actinic Keratosis
A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities
The purpose of this trial is to evaluate the safety of a simultaneous treatment regimen compared to a sequential treatment regimen when two separate areas with AKs (one located on face/scalp and the other located on trunk/…
- Trial name
- NCT01787383
- Testing
- Ingenol mebutate gel 0.05 %, Ingenol mebutate gel 0.015 %
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- LEO Pharma
Actinic Keratosis
Observational Trial Tolerability and Efficacy of Resiquimod Gel in Patients Treated for Actinic Keratosis.
Determine the recurrence rate of actinic keratosis (AK) lesions in patients with complete clinical clearance at the end of the previous trial SP848-AK-1101 at 6 and 12 months of follow-up.
- Trial name
- NCT01806961
- Where
- 9 sites in Germany, Switzerland
- Volunteers
- 16 people
- Sponsor
- Spirig Pharma Ltd.
Skin Cancer, Actinic Keratoses
Validation of SHADE a Mobile Technology for Monitoring of Ultraviolet Exposure
This study will evaluate the safety and effectiveness of Shade for the management of UV-induced skin complications and data collected from this study will be used to support the proposed indications for use.
- Conditions
- Skin Cancer, Actinic Keratoses, Ultraviolet-Induced Change in Normal Skin, Behavior, Health
- Trial name
- NCT03315286
- Testing
- SHADE Ultraviolet Sensor, Standard of care counseling
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Weill Medical College of Cornell University
Advanced Hematologic Malignancies, Leukemia
Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies
This is a clinical research study designed to evaluate whether a conditioning regimen consisting of the combination of three drugs named melphalan, alemtuzumab and clofarabine supported by donor blood cells will result in rapid…
- Conditions
- Advanced Hematologic Malignancies, Leukemia, Preleukemia
- Trial name
- NCT00943592
- Testing
- Clofarabine, Melphalan, Campath
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- University of Chicago
Actinic Keratosis (AK)
Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%
The purpose of the study is to compare the risk of developing squamous skin cancer (SCC) or other types of cancer after treatment of AKs with ingenol mebutate gel or imiquimod cream.
- Trial name
- NCT01926496
- Testing
- Ingenol Mebutate Gel, 0.015%, Imiquimod Cream, 5%
- Where
- 46 sites in France, Germany and 1 more
- Volunteers
- 485 people
- Sponsor
- LEO Pharma